Safety and Efficacy of Dexmedetomidine Addition to Intrathecal Morphine for Postoperative Analgesia in Cancer Patients Undergoing Major Abdominal Surgery
Description:
Opioids, administered intrathecal or epidural, are widely used for postoperative, and chronic
nociceptive pain secondary to cancers. Intrathecal injection of morphine to provide
postoperative analgesia during the initial 24 h after operation is a widely used
technique.The Human studies on the antinociceptive effects of co-administrated intrathecal
morphine and dexmedetomidine in postoperative pain are still lacking. In this study, the
investigators aimed to compare the synergistic interaction and side-effects of combined
intrathecal morphine and dexmedetomidine with either drug alone for postoperative analgesia
in cancer patients undergoing major abdominal surgery. Patients were randomly allocated into
three groups of 30 patients each to receive either; hyperbaric bupivacaine 0.5% (Group
I/Bupivacaine Group), bupivacaine and 0.5 mg morphine (Group II/Morphine Group), bupivacaine
and 0.5 mg morphine plus 5 µg of dexmedetomidine (Group III/Morphine-DEX Group). The assigned
drugs were dissolved in 1ml physiological saline and administered intrathecal with
bupivacaine before induction of general anesthesia.
Condition:
Postoperative Pain
Treatment:
Dexmedetomidine (Precedex)
Start Date:
May 2013
Sponsor:
Assiut University
For More Information:
https://clinicaltrials.gov/show/NCT02435537